Anti-Obesity Meds and Investigational Agents: A Clinical Practice Statement from the Obesity Medicine Association (OMA) in 2022.
It covers FDA-approved anti-obesity drugs, investigational agents, pharmacokinetics in obese individuals, and combination therapies. They touch on semaglutide, liraglutide, and newer stuff like tirzepatide. Talks about using these meds *after* bariatric surgery, too.
Basically, it's a guide for doctors treating obesity and pre-obesity, hoping that new meds will keep improving outcomes. They think anti-obesity drugs will eventually become standard care, like diabetes or hypertension meds.
It covers FDA-approved anti-obesity drugs, investigational agents, pharmacokinetics in obese individuals, and combination therapies. They touch on semaglutide, liraglutide, and newer stuff like tirzepatide. Talks about using these meds *after* bariatric surgery, too.
Basically, it's a guide for doctors treating obesity and pre-obesity, hoping that new meds will keep improving outcomes. They think anti-obesity drugs will eventually become standard care, like diabetes or hypertension meds.